blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3111959

EP3111959 - RADIOTHERAPEUTIC PARTICLES AND SUSPENSIONS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  20.07.2018
Database last updated on 23.04.2024
FormerThe patent has been granted
Status updated on  11.08.2017
FormerGrant of patent is intended
Status updated on  02.03.2017
FormerExamination is in progress
Status updated on  02.12.2016
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Oncoinvent AS
Gullhaugveien 7
0484 Oslo / NO
[2017/40]
Former [2017/01]For all designated states
Oncoinvent AS
Kjelsåsveien 168B
0884 Oslo / NO
Inventor(s)01 / Westrøm, Sara
Leiv Eirikssons gate 7
N-0271 Oslo / NO
02 / Larsen, Roy Hartvig
Lunden 20
N-0598 Oslo / NO
 [2017/01]
Representative(s)(deleted)
[N/P]
Former [2017/01]COPA Copenhagen Patents
Rosenørns Allé 1, 2nd floor
1970 Frederiksberg C / DK
Application number, filing date15175318.303.07.2015
[2017/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3111959
Date:04.01.2017
Language:EN
[2017/01]
Type: B1 Patent specification 
No.:EP3111959
Date:13.09.2017
Language:EN
[2017/37]
Search report(s)(Supplementary) European search report - dispatched on:EP18.12.2015
ClassificationIPC:A61K51/02, A61K51/10, A61K51/12, A61P35/00, // A61K103/00
[2017/01]
CPC:
A61K51/02 (EP,CN,RU,US); A61K51/025 (KR,US); A61K51/1093 (EP,CN,KR,US);
A61K51/10 (RU); A61K51/103 (EP,CN,US); A61K51/12 (RU);
A61K51/1244 (EP,CN,KR,US); A61K9/0019 (CN); A61K9/10 (CN);
A61P35/00 (EP,CN,KR,RU); A61P43/00 (EP); C01F11/18 (KR,US);
C01P2004/64 (KR,US); C01P2006/44 (KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/01]
TitleGerman:RADIOTHERAPEUTISCHE PARTIKEL UND SUSPENSIONEN[2017/01]
English:RADIOTHERAPEUTIC PARTICLES AND SUSPENSIONS[2017/01]
French:PARTICULES ET SUSPENSIONS RADIOTHÉRAPEUTIQUES[2017/01]
Examination procedure03.07.2015Examination requested  [2017/01]
03.07.2015Date on which the examining division has become responsible
18.01.2016Despatch of a communication from the examining division (Time limit: M04)
23.02.2016Reply to a communication from the examining division
31.05.2016Despatch of a communication from the examining division (Time limit: M04)
01.07.2016Reply to a communication from the examining division
03.03.2017Communication of intention to grant the patent
19.05.2017Fee for grant paid
19.05.2017Fee for publishing/printing paid
19.05.2017Receipt of the translation of the claim(s)
Opposition(s)14.06.2018No opposition filed within time limit [2018/34]
Fees paidRenewal fee
27.07.2017Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL13.09.2017
CY13.09.2017
EE13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
MC13.09.2017
MK13.09.2017
SM13.09.2017
IS13.01.2018
[2020/34]
Former [2020/31]CY13.09.2017
EE13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
MC13.09.2017
MK13.09.2017
SM13.09.2017
IS13.01.2018
Former [2019/15]EE13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
MC13.09.2017
SM13.09.2017
IS13.01.2018
Former [2018/24]EE13.09.2017
HR13.09.2017
LT13.09.2017
LV13.09.2017
SM13.09.2017
IS13.01.2018
Former [2018/15]HR13.09.2017
LT13.09.2017
LV13.09.2017
Former [2018/11]HR13.09.2017
LT13.09.2017
Former [2018/07]LT13.09.2017
Documents cited:Search[Y]WO9951278  (DU PONT PHARM CO [US]) [Y] 1-15 * page 3, line 28 - page 4, line 2 * * page 10, lines 30-35 ** example 3 *;
 [XY]EP1812115  (ALGETA AS [NO], et al) [X] 1,2,4,6-15 * paragraphs [0019] - [0022] - [0043] - [0046] - [0057] , [0065] - [0070] - [0085] - [0087] * * examples 1,2 * * claims 1-14 * [Y] 1-15;
 [XY]WO2012131378  (ALGETA ASA [NO], et al) [X] 1,2,4-7,9-12,14,15 * page 5, lines 11-17 * * page 6, lines 18-21, 25-27 * * page 8, lines 11-26 * * page 11, line 25 - page 12, line 24 * * page 14, lines 4-6, 23-25 * * page 16, line 16 - page 17, line 10 * * examples 1-7 * [Y] 1-15;
 [X]  - MARIO VOLTAGGIO ET AL, "Implantation of recoiling radionuclides of U and Th radioactive series applied to estimation of sur cial erosion of CaCO 3 materials", APPLIED GEOCHEMISTRY, (20010601), vol. 16, pages 835 - 848, XP055234427 [X] 1-3 * abstract *
 [XY]  - VERGOTE I ET AL, "Therapeutic efficacy of the alpha-emitter <211>At bound on microspheres compared with <90>Y and <32>P colloids in a murine intraperitoneal tumor model", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 47, no. 3, doi:10.1016/0090-8258(92)90141-5, ISSN 0090-8258, (19921201), pages 366 - 372, (19921201), XP026232121 [X] 1,2,4,6-15 * the whole document * [Y] 1-15

DOI:   http://dx.doi.org/10.1016/0090-8258(92)90141-5
by applicantUS4970062
 US8142758
    - BLOOMER, W.D.; MCLAUGHLIN, W.H.; NEIRINCKX, R.D.; ADELSTEIN, S.J.; GORDON, P.R.; RUTH, T.J.; WOLF, A.P., "Astatine-211-tellurium radiocolloid cures experimental malignant ascites", SCIENCE, (1981), vol. 212, pages 340 - 341
    - BOUDOUSQ V1; BOBYK L; BUSSON M; GARAMBOIS V; JARLIER M; CHARALAMBATOU P; PELEGRIN A; PAILLAS S; CHOUIN N; QUENET F, "Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb", PLOS ONE, (20130729), vol. 8, no. 7
    - GUSTAFSSON AM1; BACK T; ELGQVIST J; JACOBSSON L; HULTBORN R; ALBERTSSON P; MORGENSTERN A; BRUCHERTSEIFER F; JENSEN H; LINDEGREN S, "Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model", NUCL MED BIOL., (201201), vol. 39, no. 1, pages 15 - 22
    - KIRBY, H. W; SALUTSKY, MURRELL L, The Radiochemistry of Radium (PDF, NATIONAL ACADEMIES PRESS, (1964), page 5
    - LIU S., "Bifunctional coupling agents for radiolabeling of biomolecules and target specific delivery of metallic radionuclides", ADV DRUG DELIV REV., (2008), vol. 60, no. 12, pages 1347 - 1370
    - RITTER MA; CLEAVER JE; TOBIAS CA, "High-LET radiations induce a large proportion of non-rejoining DNA breaks", NATURE, (19770414), vol. 266, no. 5603, pages 653 - 5
    - OTT A. GERBER; VIKTORIYA Y. RYBALKO; CHAD E. BIGELOW; T AMIT A. LUGADE; THOMAS H. FOSTER; JOHN G. FRELINGER; EDITH M. LORD, "Preferential Attachment of Peritoneal Tumor Metastases to Omental Immune Aggregates and Possible Role of a Unique Vascular Microenvironment in Metastatic Survival and Growth", AM J PATHOL., (200611), vol. 169, no. 5, pages 1739 - 1752
    - VERGOTE I; LARSEN RH; DE VOS L; NESLAND JM; BRULAND 0; BJORGUM J; ALSTAD J; TROPE C; NUSTAD K, "Therapeutic efficacy of the alpha-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model", GYNECOL ONCOL., (199212), vol. 47, no. 3, pages 366 - 72
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.